# Peter A. Fasching

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/peter-a-fasching/

## Facts

| Field | Value |
| --- | --- |
| Citations | 81,246 |
| Field | Breast Cancer Treatment Studies |
| h-index | 123 |
| i10-index | 715 |
| Last Known Institution | Universitätsklinikum Erlangen |
| OpenAlex ID | https://openalex.org/A5017728105 |
| ORCID iD | https://orcid.org/0000-0003-4885-8471 |
| Works | 2,039 |

## Researcher papers

Showing 12 of 28.

- [Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis](https://scholariq.org/papers/pathological-complete-response-and-long-term-clinical-benefit-in-breast-cancer/)
- [Pembrolizumab for Early Triple-Negative Breast Cancer](https://scholariq.org/papers/pembrolizumab-for-early-triple-negative-breast-cancer/)
- [Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes](https://scholariq.org/papers/definition-and-impact-of-pathologic-complete-response-on-prognosis-after/)
- [Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-emtansine-for-residual-invasive-her2-positive-breast-cancer/)
- [Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy](https://scholariq.org/papers/tumour-infiltrating-lymphocytes-and-prognosis-in-different-subtypes-of-breast/)
- [Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes](https://scholariq.org/papers/polygenic-risk-scores-for-prediction-of-breast-cancer-and-breast-cancer-subtypes/)
- [Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial](https://scholariq.org/papers/neoadjuvant-carboplatin-in-patients-with-triple-negative-and-her2-positive-early/)
- [Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk](https://scholariq.org/papers/common-genetic-variation-in-cellular-transport-genes-and-epithelial-ovarian/)
- [Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies](https://scholariq.org/papers/associations-of-breast-cancer-risk-factors-with-tumor-subtypes-a-pooled-analysis/)
- [A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study](https://scholariq.org/papers/a-randomised-phase-ii-study-investigating-durvalumab-in-addition-to-an/)
- [RAD51B in Familial Breast Cancer](https://scholariq.org/papers/rad51b-in-familial-breast-cancer/)
- [Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche](https://scholariq.org/papers/parent-of-origin-specific-allelic-associations-among-106-genomic-loci-for-age-at/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)

## Researcher university

- [Universitätsklinikum Erlangen](https://scholariq.org/institutions/universitatsklinikum-erlangen/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.